1. Executive Summary (Confidence: High)

Alentis Therapeutics has established itself as a leading innovator in the targeting of Claudin-1 (CLDN1), a transmembrane protein that plays a pivotal role in the tight junction complex of epithelial and endothelial cells.^[1] While historically considered a difficult target due to its structural complexity, Alentis has successfully pioneered the development of antibodies that selectively bind to exposed CLDN1 epitopes found in pathological states such as cancer and fibrosis.^[3] The organization is headquartered in the life sciences hub of Basel, Switzerland, and has strategically transitioned from a focus on purely monoclonal antibodies to a robust expansion into the antibody-drug conjugate (ADC) space.^[2] This pivot is supported by significant financial backing, most recently evidenced by an oversubscribed $181.4 million Series D financing round in late 2024, which followed a $105 million Series C in 2023.^[1] The company's lead programs, including ALE.C04 for oncology and ALE.F02 (Lixudebart) for fibrosis, are currently undergoing rigorous clinical evaluation to address high unmet medical needs in "T-cell excluded" tumors and multi-organ fibrotic conditions.^[3]